Contact Us
Drug Search Results
More Filters [+]

Phenylephrine

Alternative Names: phenylephrine, neosynephrine, FENILEFRINA, vazculep, biorphen, prefrin-a, omidria, cyclomydril, duo-medihaler, prometh vc w/ codeine, prometh vc plain, pherazine vc, pherazine vc w/ codeine
Latest Update: 2024-12-09
Latest Update Note: Clinical Trial Update

Product Description

Phenylephrine is effective for the management of spinal anesthesia-induced hypotension in parturients undergoing cesarean delivery under spinal anesthesia. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/22104076/)

Mechanisms of Action: ADRA1A Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous,Oral,Ophthalmic

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Miosis | Pain Unspecified | Pain, Postoperative | Cataract

Known Adverse Events: Inflammation | Capsule Opacification

Company: AFT
Company Location: NEW YORK NY 10019
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Phenylephrine

Countries in Clinic: Brazil

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Common Cold|Influenza, Human

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
RESFRIN

P3

Not yet recruiting

Common Cold|Influenza, Human

2025-10-30

34%
RESFRIN

P3

Not yet recruiting

Common Cold|Influenza, Human

2025-10-30

34%
RESFRIN

P3

Not yet recruiting

Common Cold|Influenza, Human

2025-10-30

34%
2022-003559-32

P3

Active, not recruiting

Influenza, Human

2024-03-16

non available

P3

Active, not recruiting

Common Cold

2022-04-28

Recent News Events

Date

Type

Title

12/02/2024

News Article

 New Biovanta Study Shows Best Efficacy in Treating Common Cold

11/07/2024

News Article

 FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review

11/06/2024

News Article

 Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024

10/23/2024

News Article

 Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions